Tim Miller

Human testing has begun of ISIS-SOD1-Rx, a compound designed to block production of a toxic protein in people with the SOD1-related form of familial (inherited) ALS

posted on March 5, 2010 - 12:35pm
Isis Pharmaceuticals of Carlsbad, Calif., has begun a phase 1 clinical trial of its experimental compound ISIS-SOD1-Rx in people with familial (inherited) ALS caused by toxic SOD1 protein molecules.

Some children with MD have cognitive or emotional problems, along with physical disabilities

posted on December 1, 2002 - 7:45pm
Nancy Von Wald, director of the Turning Point School in Tucson, Ariz., asks a child to put a group of cards in a sequence and to tell a story about them.